Phreesia (NYSE:PHR) Stock Price Down 5.2% - Should You Sell?

Key Points

• Phreesia Inc. shares recently saw a decline of 5.2%, trading at $22.30 after previously closing at $23.52, with volume down by 69% compared to average trading.
• Analysts have adjusted their price targets for Phreesia, with Canaccord Genuity increasing its target to $38.00 and Needham raising it to $35.00, as most analysts currently have a "Buy" rating for the stock.
• Phreesia reported a quarterly EPS of $0.01, beating estimates, and a revenue of $117.26 million, which is a 14.9% increase compared to the same quarter last year.

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) traded down 5.2% during mid-day trading on Wednesday . The company traded as low as $22.42 and last traded at $22.30. 188,902 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 605,660 shares. The stock had previously closed at $23.52.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a research report on Friday, September 5th. Raymond James Financial set a $33.00 price target on Phreesia and gave the company an "outperform" rating in a research report on Friday, September 5th. Stephens reaffirmed an "overweight" rating and issued a $32.00 price target on shares of Phreesia in a research report on Wednesday, September 3rd. Mizuho assumed coverage on Phreesia in a research report on Wednesday, August 27th. They issued an "outperform" rating and a $36.00 price target on the stock. Finally, Needham & Company LLC increased their price target on Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the stock. According to data from MarketBeat.com, Phreesia presently has an average rating of "Buy" and an average price target of $34.08.

Phreesia Stock Down 4.4%

The firm has a 50-day moving average price of $27.17 and a two-hundred day moving average price of $26.37. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -53.58 and a beta of 0.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.08. The firm had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The firm's quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, sell-side analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Insider Transactions at Phreesia

In related news, CFO Balaji Gandhi sold 4,183 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $97,380.24. Following the transaction, the chief financial officer owned 99,125 shares in the company, valued at $2,307,630. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 3,133 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $72,936.24. Following the transaction, the general counsel owned 139,037 shares in the company, valued at $3,236,781.36. This represents a 2.20% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 94,812 shares of company stock worth $2,782,535. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new position in shares of Phreesia in the 1st quarter valued at approximately $774,000. Principal Financial Group Inc. purchased a new position in shares of Phreesia in the 1st quarter valued at approximately $1,623,000. Deutsche Bank AG grew its stake in shares of Phreesia by 30.6% in the 1st quarter. Deutsche Bank AG now owns 74,857 shares of the company's stock valued at $1,913,000 after purchasing an additional 17,560 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Phreesia by 105.2% in the 1st quarter. Acadian Asset Management LLC now owns 225,317 shares of the company's stock valued at $5,754,000 after purchasing an additional 115,527 shares during the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of Phreesia by 23.2% in the 1st quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock valued at $1,222,000 after purchasing an additional 8,978 shares during the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.